CANCER OF UNKNOWN PRIMARY SITE
Clinical trials for CANCER OF UNKNOWN PRIMARY SITE explained in plain language.
Never miss a new study
Get alerted when new CANCER OF UNKNOWN PRIMARY SITE trials appear
Sign up with your email to follow new studies for CANCER OF UNKNOWN PRIMARY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancer? sintilimab tested in advanced CUP
Disease control CompletedThis study tested a drug called sintilimab in people with advanced cancer of unknown primary (CUP), a rare cancer where doctors can't find where it started. Ten participants received the drug every three weeks for up to 24 months. The goal was to see if the drug could shrink tumo…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
Personalized medicine takes on mysterious cancers in major trial
Disease control CompletedThis study tested whether using a person's tumor genetic profile to choose treatment (targeted therapy or immunotherapy) works better than standard chemotherapy for cancer of unknown primary site. About 529 adults whose cancer was controlled after initial chemo were randomly assi…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Immunotherapy shows promise for mysterious cancers
Disease control CompletedThis study tested the drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a type of cancer where doctors cannot find where it started. The goal was to see if the drug could shrink tumors and improve survival. Participants received pembrolizumab intravenously, ei…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC